Thompson Street Capital Partners (TSCP), a private equity firm based in St. Louis, today announced the acquisition of Laragen by Transnetyx, a global leader in outsourced genetic services and a TSCP portfolio company. The addition of Laragen’s offerings to the Transnetyx solution suite improves access to genetic testing services for leading research institutes around the world, while supporting the Transnetyx mission to ensure researchers have the most efficient path to discovery. Terms of the transaction were not disclosed.
“Laragen is a perfect fit for Transnetyx,” stated Bob Bean, CEO of Transnetyx. “Our highly accurate, automated testing solutions and cohesive distribution network will allow us to provide researchers unparalleled access to Laragen’s enhanced sequencing services.”
Laragen provides sequencing, genotyping, and other laboratory services for genomics research to leading government, pharmaceutical, and academic research institutes. Transnetyx and Laragen have both served researchers for more than two decades.
“Thompson Street is excited to partner with Laragen to expand its offerings and support its mission of providing researchers with the tools needed to accelerate their discovery,” said Bob Dunn, Managing Partner at TSCP and a member of the Transnetyx Board of Directors. “We look forward to continuing to execute against their long-term plan for growth as they continue this important work.”
